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HPV16 L1 and L2 DNA methylation predicts high-grade
cervical intraepithelial neoplasia in women with mildly
abnormal cervical cytology
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DNA methylation changes in human papillomavirus type 16 (HPV16) DNA are common and might be important for identifying
women at increased risk of cervical cancer. Using recently published data from Costa Rica we developed a classification score
to differentiate women with cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) from those with no evident high-grade
lesions. Here, we aim to investigate the performance of the score using data from the UK. Exfoliated cervical cells at baseline
and 6-months follow-up were analyzed in 84 women selected from a randomized clinical trial of women undergoing surveil-
lance for low-grade cytology. Selection of women for the methylation study was based on detectable HPV16 in the baseline
sample. Purified DNA was bisulfite converted, amplified and pyrosequenced at selected CpG sites in the viral genome (URR,
E6, L1 and L2), with blinding of laboratory personnel to the clinical data. The primary measure was a predefined score combin-
ing the mean methylation in L1 and any methylation in L2. At the second follow-up visit, 73/84 (87%) women were HPV16
positive and of these 25 had a histopathological diagnosis of CIN2/3. The score was significantly associated with CIN2/3
(area under curve50.74, p50.002). For a cutoff with 92% sensitivity, colposcopy could have been avoided in 40% (95% CI
27–54%) of HPV16 positive women without CIN2/3; positive predictive value was 44% (32–58%) and negative predictive value
was 90% (71–97%). We conclude that quantitative DNA methylation assays could help to improve triage among HPV16 posi-
tive women.
Dynamic methylation of DNA and proteins is the main mo-
lecular mechanism underpinning epigenetics. It plays an im-
portant role in cancer and may be the predominant way that
genotype interacts with the environment.1,2 Human genes
and the human papillomavirus (HPV) genome are subject to
large changes in DNA methylation during carcinogenesis,
and these levels can be accurately measured using relatively
simple and inexpensive assays that show promise for diagno-
sis and prognosis.3–6
Cervical cancer is caused by persistent infection with one
of approximately a dozen high-risk (HR) HPV types. Testing
for HR-HPV DNA is likely to become the predominant
method for cervical screening in the near future due to its
high sensitivity.7 However, the main drawback of HR-HPV
testing is a relatively lower speciﬁcity than for cytology. To
compensate for this limitation different triage algorithms
have been suggested, including use of cytology and p16
immunochemistry8,9 which both require the use of a speci-
men that preserves morphology. An alternative is a molecular
triage test that would allow HR-HPV-positive women to be
reﬂex-tested from the original screening specimen; this is
particularly attractive in some situations such as in vaginal
self-collection approaches.10 Genotyping for HPV16 and
HPV18 has been proposed as a triage test of HR-HPV posi-
tives to improve speciﬁcity, however, better speciﬁcity comes
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at the cost of a relatively large drop in sensitivity of 50% or
more for cervical intraepithelial neoplasia grade 2/3 or cancer
(CIN21). A related problem is that the positive predictive
value (PPV) of HPV16 genotyping is usually less than 25%;
therefore, a substantial majority of women referred to colpo-
scopy on the basis of an HPV16-positive result will not have
CIN21. Meanwhile the HR-HPV-positive women not
referred to colposcopy still need careful follow-up within 1
year.11 The low PPV for HPV genotyping has prompted an
ongoing search for better molecular triage tests. The goal is
to provide an accurate determination of disease state and to
improve the cost-effectiveness of HPV-based screening by
avoiding colposcopy and frequent follow-up for most HR-
HPV infected women.9–12
Quantitative measurement of DNA methylation shows
promise as a simple test for the diagnosis and prognosis of
many cancers. In women infected by HPV16, the levels of
methylation increase slowly with duration of HPV persistence
and increase more dramatically with the diagnosis of cervical
cancer.13,14 These observations open up the possibility of accu-
rately predicting which women will develop cancer years in
advance. Of more immediate interest to clinicians looking for
efﬁcient management strategies, a study of women from Costa
Rica looking at methylation levels in the viral late regions, spe-
ciﬁcally CpG 6457 in L1 demonstrated the detection of preva-
lent CIN21 among HPV16 infected women with a sensitivity
of 90% and a speciﬁcity of 60%.13 The efﬁciency of L1 methyl-
ation triage appeared to increase with age; in women above
the median age in the study (28 years) at a sensitivity of 90%
the speciﬁcity increased to more than 75%.13
Using pilot data from a Costa Rican screening popula-
tion,13 we developed three classiﬁer scores based on methyla-
tion of selected CpG sites in HPV16 L1, L2, URR and E6
open reading frames (ORFs). Classiﬁers 1 and 2 were devel-
oped to identify women with CIN grade 2/3 while classiﬁer 3
was developed to predict persistence of HPV infection. In the
current study, we measured the methylation of relevant CpG
sites and applied the three classiﬁers with an aim to validate
the predeﬁned scores in the UK based cohort of women
under surveillance due to presence of low-grade cervical
abnormalities.15
Material and Methods
Study population—UK clinical trial
The study was conducted according to REMARK guidelines
for assessing biomarker test performance.16 Relevant details
of the cohort have been described previously.15 In brief, the
study was designed primarily as a double-blind, randomized
controlled trial of 150 mg “diindolylmethane” (DIM) or pla-
cebo daily for 6 months in women with newly diagnosed,
low-grade (borderline changes or mild dysplasia) cytological
abnormalities; this classiﬁcation group is broadly equivalent
to a combination of low-grade squamous intraepithelial
lesion or atypical squamous cells of undetermined signiﬁ-
cance in the Bethesda System.17 Randomization was in the
ratio 2 (DIM) to 1 (placebo). All women were invited for col-
poscopy at 6 months with biopsy of any abnormality. The
study protocol was reviewed and approved by the South East
Wales Local Research Ethics Committee (Ref# 03/5093) and
informed written consent was obtained from each participant
before randomization. An independent Data and Safety Mon-
itoring Committee was in place throughout the trial to review
study progress. The trial is registered at ClinicalTrials.gov
(number NCT00462813) and ISRCTN (number 47437431).
Samples from this clinical trial are well suited to our aims of
molecular investigation of DNA methylation because there
was standardized collection of exfoliated cervical cell speci-
mens in SurePath
TM
(Becton Dickinson, Sparks, MD) vials at
both baseline and at the 6-month follow-up just before col-
poscopy. The study did not reveal any signiﬁcant effects of
DIM on either HPV infection or cervical morphology and so
we do not consider this aspect further.15 The CONSORT dia-
gram is presented in Figure 1.
Test endpoints
The primary endpoint of this study was presence of histologi-
cally conﬁrmed CIN2/3 6–12 months after enrolment. No
cancers were found in our study. The secondary endpoint
was HPV16 status on a sample taken at the 6-month visit.
Cytology and histological samples were read and reported
within the routine Cervical Screening Wales program.
Women for the study were selected because they were
HR-HPV positive on their baseline sample by PCR-enzyme
immunoassay (PCR-EIA) using GP51/61 primers per-
formed at the HPV laboratory, Cardiff University School of
Medicine.18 Presence of HPV16 DNA was conﬁrmed in a
second PCR-EIA, using individual oligo-nucleotide probes.
Methylation results are only reported if the aliquot tested in
the Molecular Epidemiology Laboratory at the Centre for
Cancer Prevention, Queen Mary University of London,
What’s new?
The human papillomavirus (HPV) genome is subject to changes in DNA methylation. Here, the quantification of DNA methyla-
tion in HPV16 from exfoliated cervical cells of women with detectable virus was found to be significantly associated with cervi-
cal intraepithelial neoplasia grade 2 or 3. The methlyation score was based on the combined mean of methylation specifically
in the HPV16 late regions (L1 and L2). The approach could be used to aid decisions concerning triage to colposcopy and has
the potential to be expanded to other carcinogenic HPVs.
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conﬁrmed the presence of HPV16 DNA either on the meth-
ylation assay or by quantitative real time PCR in E6 ORF.19
DNA isolation and bisulfite conversion
Genomic DNA was extracted from cervical specimens with
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) and
measured as previously described.20 DNA (250 ng) was used
in the bisulﬁte conversion reactions where unmethylated
cytosines were converted to uracil with the EZ DNA methyl-
ation kit (Zymo research, Irvine, CA) according to manufac-
turer’s instructions.
HPV16 DNA methylation assay
Sites indicating diagnostic and/or potential to predict persist-
ence in L1, L2, E6 and URR in the Costa Rican cohort13 were
selected for development of the classiﬁer scores. Therefore,
methylation was measured in the sites constituting the scores,
namely CpG-L1 6367, 6389; CpG-L2 4238, 4247, 4259, 4268,
4275; CpG-E6 218, 220, 245; and CpG-URR 31, 37, 43, 52, 58
in baseline and 6-month follow-up specimens from the UK
clinical trial. Brieﬂy, PCRs were performed using 1.2–1.5 ml of
converted DNA equivalent of 1,500 cells using the PyroMark
PCR kit (Qiagen) as previously described.13 Thermal cycling
was initiated at 95C for 15 min, then 50 cycles: 30 sec at
94C; 30 sec at the annealing temperature13; 30 sec at 72 C,
and a ﬁnal extension for 10 min at 72 C. In each run, a non-
template negative control was run in addition to a standard
curve consisting of 1 pg/ml 0, 50 and 100% methylated HPV16
plasmid in a background of 10 ng/ml human DNA. PCR prod-
uct (10 ml) was pyrosequenced using a PyroMark
TM
Q96 ID
(Qiagen) instrument. Raw pyrogram data were analyzed by
the PSQ96MA software and the peak height proportions of cy-
tosine (C, indicating methylation) and thymidine (T, not
methylated) for individual CpG sites were converted into per-
centage methylated C by the formula C/(C1T) 3 100 at each
interrogated CpG site.
Statistical methods
We set two aims in the predeﬁned statistical analysis plan: (i)
to validate the performance of two classiﬁers (S1 and S2) to
separate HPV16 infected women with CIN2/3 from infected
women without high-grade lesions (ii) to validate the ability
of a classiﬁer (S3) to predict persistent HPV16 infection. The
three classiﬁers were developed using pilot data from the
Costa Rican study (Supporting Information Report) before
the analysis of the methylation data collected from UK clini-
cal trial.
The primary classiﬁer score (S1) for risk of CIN 2/3 was
deﬁned:
S1564xa136xb
where variable (xa) denotes the proportion of methylated L2
CpG sites (a site is methylated if measurement is >0%) and
can take values 0, 0.2, 0.4, 0.6, 0.8, 1.0. Variable (xb) is the
average methylation of CpG 6367 and 6389 expressed as a
decimal between 0 and 1. A failed methylation assay was
treated as zero methylation in both variables. In Costa Rican
data, at optimal cutoff S15 5, sensitivity was 93% and speci-
ﬁcity 52%.
To investigate if methylation of E6 and URR would con-
tribute valuable information in identifying presence of high-
grade lesions, a secondary classiﬁer score (S2) for risk of CIN
2/3 was deﬁned as:
S25 44:3xa1 37:3xb1 18:4xc
with the additional variable (xc) based on any detectable
methylation in E6 and URR. (xc) is therefore 1 if any of the
8 CpG sites in E6 or URR were methylated (meas-
urement> 0%) and 0 otherwise. In Costa Rican data, at opti-
mal cutoff S25 18, sensitivity was 90% and speciﬁcity 64%.
Because the S1 and S2 were developed using the methylation
data collected on the last cytological sample before diagnosis
in the Costa Rican study, we applied the classiﬁers scores 1
and 2 only on the methylation data from 6-month follow-up
samples.
For development of classiﬁer S1 and S2, the cancers in the
Costa Rica data were excluded to avoid a risk of bias from
the very high levels of methylation typical of these lesions
and because we desired classiﬁers that can efﬁciently detect
CIN2 and CIN3. However, we believe that our classiﬁers may
also be relevant for cancers because they mostly have more
extreme methylation values than CIN2/3.13
A third classiﬁer (S3) was deﬁned to investigate if methyl-
ation could be useful to predict women who were likely to be
HPV16 DNA positive again after the initial positive result,
i.e. persistence of the infection. As only methylation in L1
Figure 1. Consort Diagram describing the selection of patients in
the UK cohort.
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appeared to be predictive of persistence in the Costa Rica
data, the third classiﬁer (S3) was deﬁned as the mean methyl-
ation of the two CpGs in L1 (i.e. S35 xb). At 4% methylation
cutoff in the Costa Rica data, persistence was predicted.
The performance of the three classiﬁers was evaluated by
receiver operating characteristics (ROCs), area under the
ROC curve (AUC) and logistic regression likelihood ratio sta-
tistics (v2).21 A nonparametric BCa bootstrap conﬁdence
interval (5,000 replicates)22 was used for AUC and Wilson
conﬁdence intervals were used for sensitivity, speciﬁcity and
positive/negative predictive value.23 The Cuzick trend test
was used to investigate changes in methylation with increas-
ing lesion severity.
In addition, the diagnostic value of cytology at the
6-month time point was assessed. Boxplots and summary sta-
tistics were used to compare methylation across CpGs. A
Wilcoxon signed-rank test was used to look for signiﬁcant
differences in methylation between HPV161 women at base-
line and 6 months, where failed methylation was set to zero.
Analyses were performed using STATA 12.0 and R 2.11.1
software packages.
Results
Predefined primary analysis: validation of the classifiers
Presence of HPV16 DNA was conﬁrmed by quantitative real
time PCR in 82 of 84 base line samples (the negative samples
were excluded) and 73 of the 6-month samples. Of the latter,
25 women had a histopathological diagnosis of CIN2/3,
where 10 were diagnosed with CIN2 and 15 CIN3. No can-
cers were detected in this cohort. The S1 classiﬁer was
applied to the methylation data obtained from the 73 women
who were still HPV16 positive at 6 months. Overall, the S1
score showed an increasing trend (p5 0.0004), between
<CIN2 (interquartile range (IQR) 17, 68, median 70), CIN2
(IQR 69, 70, median 73) and CIN3 (IQR 71, 74, median 77).
At the predeﬁned cut-point from Costa Rica data (S15 5),
the S1 classiﬁer had 96% sensitivity for CIN2/3, but a low
speciﬁcity of 15% (Table 1). Figure 2 shows the ROC curve
for S1 with AUC5 0.74 (95% CI 0.60–0.85) and v2 of 9.78
(p5 0.002). Supporting Information Table 1 shows various
points along the ROC plot with different tradeoffs of sensitiv-
ity and speciﬁcity. To account for the difference between the
two investigated populations, we investigated at which cut-
point a minimum of 90% sensitivity would be retained, but
optimal speciﬁcity found (Table 1). Consequently, we
obtained a cut-point of S15 67 in the UK clinical trial,
which yielded sensitivity of 92% and speciﬁcity of 40% (27–
54%), PPV 44% (32–58%) and negative predictive value
(NPV) 90% (71–97%). At S15 67, two CIN3 were missed
and at S15 5 one CIN3 was missed.
Next, classiﬁer S2 was applied to the 73 HPV16 positive
women at 6 months. S2 performed slightly better than S1 at
the predeﬁned cut-point (S25 18) but equally at the cut-
point maximizing the speciﬁcity with 90% sensitivity
(S25 56) (Table 1).
Lastly, classiﬁer S3 was applied to the 82 baseline samples,
where it displayed a sensitivity of 92% and speciﬁcity of 27%
at the predeﬁned cutoff of 4 for predicting 6-month HPV16
persistence. The corresponding PPV was 89% and NPV 39%.
Figure 3 shows the ROC for S3 with AUC5 0.69, and v2 5
2.7 (p5 0.10). Although statistical signiﬁcance was not
attained this might be due to lack of power because only 11
women (12%) cleared HPV16 DNA in 6 months. Supporting
Information Table 2 shows the values of sensitivity and speci-
ﬁcity for other selected points along the ROC.
Cytology
Cytology results were available for 67 HPV16 positive women
at 6 months, of whom 24 were CIN2/3 (Supporting Informa-
tion Table 3). Cytology showed 67% sensitivity (95% CI 45–
84%) and 42% speciﬁcity (95% CI 27–58%) with correspond-
ing PPV 39% and NPV 69% if any cervical abnormality pres-
ent (borderline or worse) was used as a cut-point to predict
CIN2/3.
Exploratory analysis of methylation in UK clinical trial
The distribution of methylation of each investigated CpG site
in women with and without CIN2/3 is shown in Figure 4.
Table 1. The sensitivity and specificity of classifiers S1, S2 and S3 at the predefined cut-points and at cut-points with maximized specificity
and sensitivity of at least 90%
Classifier
(cut-point)
Number of
classified CIN2/3
(total525)
Sensitivity
(%)
Number of classified
<CIN2 (total548)
Specificity
(%)
S1 (5) 24 96 41 15
S1 (67) 23 92 29 40
S2 (18) 24 96 35 27
S2 (56) 23 92 29 40
Number of classified
persistent (total 571)
Number of classified
clearer (total511)
S3 (4)1 67 94 8 27
1The S3 classifier did not show significant ability to predict persisitence of infection; therefore, cut-point for maximized specificity was not explored.
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This demonstrated that methylation was relatively high in the
L2 and L1 regions with median methylation between 11% in
CpG 4259 and 33% in CpG 4238, while methylation was
very low to non-detectable in the URR and the E6 regions,
i.e. <5%. Further, the methylation of L1 was higher in
women with CIN2/3, who also had a greater proportion of
sites in L2 that were methylated (Fig. 4) concurring with the
S1 classiﬁer score showing that these combined patterns had
signiﬁcant power to predict CIN2/3.
Mean methylation, number of unmethylated, and number
failed methylation assays in each ORF at baseline and 6
months, separated by whether they cleared HPV16 infection
or were diagnosed with CIN2/3 are presented in Table 2. The
methylation was greater in the 6-month samples than at
baseline; signiﬁcantly so for L2 (average 14.2% from 71 who
persisted at baseline to 73 HPV161 at 6 months, p5 0.004),
URR (10.9%, p< 0.001), and E6 (11.1%, p5 0.002), but
non-signiﬁcantly for L1 (12.0%, p5 0.141). For persistent
infections, paired differences in methylation between baseline
and 6-month samples are shown in the Supporting Informa-
tion Figure 1 where changes in the distributions can be more
readily appreciated.
Discussion
We have conﬁrmed the diagnostic value of HPV16 DNA
methylation classiﬁer S1 for identifying women with CIN2/3
in a clinical study of women with low-grade cytology and
persistent HPV16 infection over at least 6 months. We found
that for a cutoff with 92% sensitivity, colposcopy could have
been avoided in 40% (95% CI 27–54%) of HPV16 positive
women without CIN2/3; PPV was 44% (32–58%) and NPV
was 90% (71–97%). As a relatively low proportion of
HPV16-positive women with low-grade lesions progress to
CIN21, a methylation test with PPV of 44 and 90% NPV
could help triage women and identify those at lower risk who
could be followed-up less frequently. Validation is a sequen-
tial process and additional validations are required before
one may consider our assay to be qualiﬁed for clinical use. In
addition, a cutoff needs to be validated in comparable popu-
lations with standardized sample collection and storage. If
conﬁrmed by other studies and extended to different popula-
tions, the methylation classiﬁer could lead to an advance in
the triage of women positive for HPV16 DNA and could
potentially be extended to other HPV types. The methylation
patterns of several other HPV types have recently been
reported to be similar to HPV16 encouraging the possibility
of developing a HR-HPV group methylation test.24 Our study
provides a model for the study of methylation of other HPV
types and suggests the HPV methylation test as a possible
second molecular test on top of the available HR-HPV tests
to triage HPV infected women for colposcopy. All unmethy-
lated HPV16 infections could be treated as of lower risk but
still be more frequently called for repeat testing than HPV16
negative women. In comparison to cytology, the sensitivity of
the S1 classiﬁer was higher (92 vs. 67%) while the speciﬁcity
was similar (42 vs. 40%). This suggests that the methylation-
based classiﬁer score may be preferred for triage if conﬁrmed
in larger studies.
There are several ongoing studies in different populations
of women from Costa Rica, the USA and Europe that are eval-
uating the potential value of epigenetic testing for cervical can-
cer. This new approach to triage may become more important
when HPV DNA testing becomes the primary screening
method. Most assays to test for DNA methylation are still in
the research realm but some such as quantitative methylation-
speciﬁc PCR (qMSP) have made the transition to clinical util-
ity25,26; however, we did not choose the qMSP assay because
pyrosequencing (PSQ) may be a simpler and more accurate
test for quantitative HPV CpG methylation measure-
ments.13,20,27 PSQ is inherently quantitative as it takes the ratio
of C to C1T in CpG sites that are treated with sodium bisul-
ﬁte reagent. Bisulﬁte converts all nonmethylated C’s to T’s and
these changes can be precisely measured by the pyrosequenc-
ing method and compared to internal controls. There is no
need to take ratios to external controls such as for qMSP that
may lead to potential problems of increased variability.
Although pyrosequencing-based measurement of DNA meth-
ylation is still somewhat in the research realm, it appears ready
for the transition to a more clinical setting, and furthermore,
simpler methylation assays could be developed, perhaps based
on high-resolution melt analyses or next generation sequenc-
ing.28,29 It appears that quantitative DNA methylation testing
of HPV in routine settings may be feasible given sufﬁcient
attention from developers of diagnostic tests.
Figure 2. ROC curve resulting from application of classifier S1 to
the 6-month samples of women with HPV16, to separate those
with and without CIN 2/3. AUC50.74 (95% CI 0.60–0.85).
Selected sensitivity and specificity points with corresponding S1
scores are shown. The sensitivity and 1-specificity values range
from 0 to 1 and these correspond to percentages of 0% to 100%
respectively.
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There are numerous human genes, MAL, CADM1, hsa-
mir-124 etc. that appear to have potential for triage of women
with HR-HPV infections or abnormal cytology.25,26,30 One of
the more promising to date are a combination of MAL and
CADM1 which could be a possible triage test for HR-HPV
screening, giving a reported sensitivity of 87% and speciﬁcity
of 43%.26 In the same set of women, the triage sensitivity and
speciﬁcity values for cytology were 66 and 79%, respectively,
while cytology combined with genotyping for HPV16 and
HPV18 had a sensitivity of 84% and a speciﬁcity of 54%.26 Use
of human genes as DNA methylation diagnostic targets has the
advantage of being non-HPV type speciﬁc and if combined
with an HPV DNA methylation test, may be a source of an
effective triage tool to detect women at high risk of developing
CIN21. A study of a combination test is underway.
To reach 90% sensitivity with highest possible speciﬁcity,
the cutoff value in S1 was adjusted to 67 in the UK cohort,
compared to 5 in the Costa Rica cohort. The large difference
in the cutoff, may be due to a number of factors, such as dif-
ferences between the populations, study size or storage of the
specimens in different media—SurePath in the UK and STM
(standard transport medium) in the Costa Rican cohort,
respectively. It is also possible that the methylation risk clas-
siﬁer may have different forms and cutoffs depending on the
speciﬁc clinical application.
Table 2. Mean methylation, number and percentage of unmethylated specimens and failed assays in each region at baseline and six months
URR E6
Number
of cases
Mean
methylation1
Unmethylated
N (%)2 Failed N (%)
Mean
methylation
Unmethylated
N (%)
Failed
N (%)
First Clear 11 1.6 3 (27) 0 (0) 2.0 3 (27) 1 (9)
sample Persist 71 1.6 14 (20) 0 (0) 2.5 7 (10) 0 (0)
Total 82 1.6 17 (21) 0 (0) 2.5 10 (12) 1 (1)
First <CIN2 57 1.7 12 (21) 0 (0) 2.4 6 (11) 1 (2)
sample CIN2/3 25 1.6 5 (20) 0 (0) 2.6 4 (16) 0 (0)
Total 82 1.6 17 (21) 0 (0) 2.5 10 (12) 1 (1)
Second <CIN2 48 2.3 5 (10) 1 (2) 3.2 6 (13) 2 (4)
sample CIN2/3 25 3.0 2 (8) 0 (0) 4.2 2 (8) 0 (0)
Total 73 2.5 7 (10) 1 (1) 3.6 8 (11) 2 (3)
L2 L1
First Clear 11 11.0 3 (27) 2 (18) 14.2 0 (0) 1 (9)
sample Persist 71 15.3 14 (20) 2 (3) 20.0 2 (3) 1 (1)
Total 82 14.8 17 (21) 4 (5) 19.3 2 (2) 2 (2)
First <CIN2 57 13.0 15 (26) 3 (5) 16.2 1 (2) 2 (4)
sample CIN2/3 25 18.7 2 (8) 1 (4) 25.9 1 (4) 0 (0)
Total 82 14.8 17 (21) 4 (5) 19.3 2 (2) 2 (2)
Second <CIN2 48 17.1 10 (21) 3 (6) 20.0 0 (0) 1 (2)
sample CIN2/3 25 22.4 1 (4) 0 (0) 25.7 0 (0) 0 (0)
Total 73 19.0 11 (15) 3 (4) 22.0 0 (0) 1 (1)
1Mean methylation is stated in percent
2n (%) means number of cases and (percentage) of cases
Figure 3. ROC curve resulting from application of classifier S3 to
separate women positive for HPV16 DNA only at baseline from
women positive at both time points. AUC50.69, v2 5 2.7
(p50.10). Selected sensitivity and specificity points with
corresponding S3 scores are shown. The sensitivity and 1-specificity
values range from 0 to 1 and these correspond to percentages of
0% to 100% respectively.
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A potential limitation to our study is that the validation
of the classiﬁer score was performed in women with low-
grade cytology, which is not the target population for
intended use in a setting for triage of primary HPV16 DNA-
positive women. Although not a screening population, the
advantage of our cohort was the high disease rate, allowing a
more accurate evaluation of sensitivity and speciﬁcity in this
relatively small study. Furthermore, the classiﬁer score was
developed on methylation data obtained from Costa Rican
women who entered the study without any evidence of cervi-
cal disease and then followed for years without any evident
cervical abnormalities until the incident CIN21 were
detected. The Costa Rican population used to derive the risk
scores is ethnically different to the UK cohort and the fact
that the scores worked similarly in both populations of
women from different continents is encouraging. Another li-
mitation is the relatively small sample size of our study and
thus the rather wide conﬁdence intervals. Larger studies on
different populations of women are necessary to show that
methylation testing of the HPV genome is a robust and feasi-
ble test in the routine setting. Expansion of methylation pan-
els to other HR-HPV types is also desirable.
In conclusion, a predeﬁned classiﬁer score based on
HPV16 methylation in L1 and L2 in a Central American
population was found to have similar differentiating potential
to identify CIN2/3 in European women. Our successful vali-
dation of the predeﬁned classiﬁers indicates the generality of
our approach to test for DNA methylation in the L1 and/or
the L2 regions of HPV16.
Acknowledgements
The authors gratefully recognize the patients who participated in this study.
Sponsors had no role in study design, execution, data analyses or the content
of the paper.
References
1. Lorincz AT. The promise and the problems of
epigenetics biomarkers in cancer. Expert Opin
Med Diagn 2011;5:375–9.
2. Robertson KD. DNA methylation and human
disease. Nat Rev Genet 2005;6:597–610.
3. Turan T, Kalantari M, Cuschieri K, et al. High-
throughput detection of human papillomavirus-
18 L1 gene methylation, a candidate biomarker
for the progression of cervical neoplasia. Virology
2007;361:185–93.
4. Brandsma JL, Sun Y, Lizardi PM, et al. Distinct
human papillomavirus type 16 methylomes in
cervical cells at different stages of premalignancy.
Virology 2009;389:100–7.
5. Mirabello L, Sun C, Ghosh A, et al. Methylation
of human papillomavirus type 16 genome and
risk of cervical precancer in a Costa Rican
population. J Natl Cancer Inst 2012;104:
1–10.
6. Badal S, Badal V, Calleja-Macias IE, et al. The
human papillomavirus-18 genome is efﬁciently
targeted by cellular DNA methylation. Virology
2004;324:483–92.
7. Franceschi S, Denny L, Irwin KL, et al. Eurogin
2010 roadmap on cervical cancer prevention. Int
J Cancer 2011;128:2765–74.
8. Doeberitz MK, Vinokurova S. Host factors in
HPV-related carcinogenesis: cellular mechanisms
controlling HPV infections. Arch Med Res
2009;40:435–42.
9. Cuzick J, Bergeron C, Doeberitz MK, et al. New
technologies and procedures for cervical cancer
screening. Vaccine 2012;30:F107–16.
10. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A,
et al. Self-collection of vaginal specimens for
human papillomavirus testing in cervical cancer
prevention (MARCH): a community-based
randomised controlled trial. Lancet
2011;378:1868–73.
11. Castle PE, Stoler MH, Wright TC, Jr, et al.
Performance of carcinogenic human
papillomavirus (HPV) testing and HPV16 or
HPV18 genotyping for cervical cancer screening
of women aged 25 years and older: a subanalysis
of the ATHENA study. Lancet Oncol
2011;12:880–90.
12. Ronco G, Giorgi-Rossi P, Carozzi F, et al.
Efﬁcacy of human papillomavirus testing for the
detection of invasive cervical cancers and cervical
intraepithelial neoplasia: a randomised controlled
trial. Lancet Oncol 2010;11:249–57.
13. Mirabello L, Schiffman M, Ghosh A, et al.
Elevated methylation of HPV16 DNA is
associated with increased risk of high grade
cervical intraepithelial neoplasia. Int J cancer
2013;132:1412–22.
14. Kalantari M, Calleja-Macias IE, Tewari D, et al.
Conserved methylation patterns of human
papillomavirus type 16 DNA in asymptomatic
infection and cervical neoplasia. J Virol
2004;78:12762–72.
15. Castanon A, Tristram A, Mesher D, et al. Effect
of diindolylmethane supplementation on low-
grade cervical cytological abnormalities: double-
blind, randomised, controlled trial. Br J Cancer
2012;106:45–52.
16. McShane LM, Altman DG, Sauerbrei W, et al.
REporting recommendations for tumor MARKer
prognostic studies (REMARK). Breast Cancer Res
Treat 2006;100:229–35.
17. Solomon D, Davey D, Kurman R, et al. The 2001
Bethesda System: terminology for reporting results
of cervical cytology. JAMA 2002;287:2114–9.
18. Jacobs MV, Snijders PJ, van den Brule AJ, et al.
A general primer GP51/GP6(1)-mediated PCR-
enzyme immunoassay method for rapid detection
of 14 high-risk and 6 low-risk human
papillomavirus genotypes in cervical scrapings. J
Clin Microbiol 1997;35:791–5.
19. Cricca M, Morselli-Labate AM, Venturoli S, et al.
Viral DNA load, physical status and E2/E6 ratio
as markers to grade HPV16 positive women for
high-grade cervical lesions. Gynecol Oncol
2007;106:549–57.
Figure 4. DNA methylation distribution in each investigated CpG
site. The box plots show the distribution of average, lower, and
upper quartile methylation values with whiskers extending to the
minima and maxima. The white box plots represent methylation in
59 <CIN2 women and the black box plots represent the results for
25 women who were CIN2/3. In the corresponding boxes below
the box plots, the proportion of unmethylated assays is illustrated
in gray for <CIN2 and black for CIN2/3. Failed assays were
excluded.
E
ar
ly
D
et
ec
ti
on
an
d
D
ia
gn
os
is
Lorincz et al. 643
Int. J. Cancer: 133, 637–645 (2013) VC 2013 UICC
20. Vasiljevic N, Wu K, Brentnall AR, et al. Absolute
quantitation of DNA methylation of 28 candidate
genes in prostate cancer using pyrosequencing.
Dis Markers 2011;30:151–61.
21. McCullagh P, Nelder JA. Generalized linear
models, 2nd ed. London: Chapman and Hall/
CRC, 1989.
22. Davidson AC, Hinkley DV. Bootstrap methods
and their applications. Cambridge: Cambridge
University Press, 1997.
23. Agresti A, Coull BA. Approximate is better than
"exact" for interval estimation of binomial
proportions. Am Statist 1998;52:119–
26.
24. Wentzensen N, Sun C, Ghosh A, et al.
Methylation of HPV18, HPV31, and HPV45
genomes is associated with cervical intraepithelial
neoplasia grade 3. J Natl Cancer Inst
2012;104:1738–49.
25. Overmeer RM, Louwers JA, Meijer CJ, et al.
Combined CADM1 and MAL promoter
methylation analysis to detect (pre-)malignant
cervical lesions in high-risk HPV-positive women.
Int J Cancer 2010;129:2218–25.
26. Hesselink AT, Heideman DA, Steenbergen RD,
et al. Combined promoter methylation analysis of
CADM1 and MAL: an objective triage tool for
high-risk human papillomavirus DNA-positive
women. Clin Cancer Res 2011;17:2459–65.
27. Quillien V, Lavenu A, Karayan-Tapon L, et al.
Comparative assessment of 5 methods
(methylation-speciﬁc polymerase chain reaction,
methylight, pyrosequencing, methylation-sensitive
high-resolution melting, and
immunohistochemistry) to analyze O6-
methylguanine-DNA-methyltranferase in a series
of 100 glioblastoma patients. Cancer
2012;118:4201–11.
28. Clarke J, Wu HC, Jayasinghe L, et al. Continuous
base identiﬁcation for single-molecule nanopore
DNA sequencing. Nat Nanotechnol 2009;4:265–
70.
29. Wojdacz TK. Methylation-sensitive high-
resolution melting in the context of legislative
requirements for validation of analytical
procedures for diagnostic applications. Expert Rev
Mol Diagn 2012;12:39–47.
30. Wilting SM, van Boerdonk RA, Henken FE, et al.
Methylation-mediated silencing and tumour
suppressive function of hsa-miR-124 in cervical
cancer. Mol Cancer 2010;9:167.
E
ar
ly
D
et
ec
ti
on
an
d
D
ia
gn
os
is
644 HPV16 DNA methylation in cervical lesions
Int. J. Cancer: 133, 637–645 (2013) VC 2013 UICC
